# Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

> **NCT03793868** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 22 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Perampanel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03793868
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793868, "Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03793868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*